Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.
You may also be interested in...
Not The Way You Want To Start Your Year: Inspire Cystic Fibrosis Drug Fails Late
Denufosol, a potentially disease-altering CF drug, was headed for an NDA filing later this year based on positive Phase III TIGER-1 data, but that was before the bad news from TIGER-2.
Not The Way You Want To Start Your Year: Inspire Cystic Fibrosis Drug Fails Late
Denufosol, a potentially disease-altering CF drug, was headed for an NDA filing later this year based on positive Phase III TIGER-1 data, but that was before the bad news from TIGER-2.
More Positive Phase IIa Data May Have Vertex CF Drug On Registration Path
With more positive safety and efficacy data for its disease-modifying cystic fibrosis candidate, VX-770, Vertex said Oct. 20 it plans to work with U.S. and EU regulatory officials to develop a registration program for the oral CF potentiator